| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Nicholas J. Vogelzang | Q7025647 |
| Michael J. Morris | Q38329744 | ||
| Susan Halabi | Q42896002 | ||
| Johann de Bono | Q43249916 | ||
| Eric J Small | Q97531370 | ||
| Ian F. Tannock | Q106114426 | ||
| Catherine M Tangen | Q114337750 | ||
| Celestia Higano | Q126877419 | ||
| P2093 | author name string | Maha Hussain | |
| Ian M Thompson | |||
| Andrew J Armstrong | |||
| Mario A Eisenberger | |||
| Karim Fizazi | |||
| Christopher J Logothetis | |||
| Daniel P Petrylak | |||
| Hua Ma | |||
| Kim N Chi | |||
| William Kevin Kelly | |||
| Abderrahim Fandi | |||
| Mark Rosenthal | |||
| David I Quinn | |||
| John C Araujo | |||
| Shaoyi Li | |||
| Haojin Zhou | |||
| Nicole C Solomon | |||
| P2860 | cites work | Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 |
| Meta-analysis in clinical trials | Q27860779 | ||
| Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial | Q28294857 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
| Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th | Q35549709 | ||
| Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Q35572535 | ||
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 | ||
| Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy | Q37325001 | ||
| Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | Q37590738 | ||
| Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Q41082307 | ||
| Visceral disease in castration-resistant prostate cancer. | Q42758807 | ||
| Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. | Q44187537 | ||
| Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. | Q44381567 | ||
| The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer | Q45892459 | ||
| A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis | Q46920684 | ||
| Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. | Q53036812 | ||
| A general parametric approach to the meta-analysis of randomized clinical trials | Q67861093 | ||
| Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer | Q83831101 | ||
| Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer | Q86563090 | ||
| Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial | Q87195630 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 1652-1659 | |
| P577 | publication date | 2016-03-07 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer | |
| P478 | volume | 34 |
| Q89584566 | 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice |
| Q37707083 | 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients |
| Q92834718 | 68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients |
| Q95261850 | A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy |
| Q38720538 | A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector |
| Q49579799 | A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. |
| Q91345206 | Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia |
| Q48368518 | Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. |
| Q28071705 | Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology |
| Q47740995 | CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer |
| Q38730590 | Cellular determinants and microenvironmental regulation of prostate cancer metastasis |
| Q91676523 | Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer |
| Q94528678 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel |
| Q57107947 | Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation |
| Q41566010 | Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer? |
| Q48109856 | Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. |
| Q37726362 | Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers |
| Q39210257 | Emerging Variants of Castration-Resistant Prostate Cancer |
| Q64970405 | Endobronchial metastases 20 years after prostate cancer excision. |
| Q38848519 | Expression of STAT3 in Prostate Cancer Metastases. |
| Q50099745 | Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series |
| Q55307923 | High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. |
| Q58609564 | Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302 |
| Q49357072 | Imaging αvβ3 integrin expression in skeletal metastases with 99mTc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment |
| Q37288432 | Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer |
| Q94571941 | Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study |
| Q52560267 | Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. |
| Q92101896 | Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials |
| Q31108842 | METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. |
| Q101476445 | Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies |
| Q55331819 | Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer. |
| Q49032788 | Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. |
| Q92063519 | Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy |
| Q91854150 | Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial |
| Q42690512 | Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features |
| Q59792587 | NSD2 is a conserved driver of metastatic prostate cancer progression |
| Q103836797 | Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience |
| Q90699186 | Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel |
| Q47399411 | Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. |
| Q38606581 | Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone |
| Q61809700 | Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis |
| Q53822455 | Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. |
| Q92863168 | Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients |
| Q64098441 | Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer |
| Q90339423 | Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis |
| Q64065989 | Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection |
| Q47557622 | Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases |
| Q92604860 | Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 |
| Q92494044 | Study on the cellular internalization mechanisms and in vivo anti-bone metastasis prostate cancer efficiency of the peptide T7-modified polypeptide nanoparticles |
| Q41485921 | Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer |
| Q38966462 | The Cohesive Metastasis Phenotype in Human Prostate Cancer |
| Q38810776 | The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer |
| Q92564901 | The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone |
| Q41711657 | The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression |
| Q41566002 | The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer |
| Q90948888 | The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience |
| Q38964037 | Therapeutic management of bone metastasis in prostate cancer: an update |
| Q92608475 | Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 |
| Q55068843 | Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL. |
| Q37688990 | c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer |
Search more.